Peter Usman Bassi1, Adeline I Osakwe2, Ambrose Isah3, Comfort Suku2, Musa Kalat2, Iliya Jalo4, Robinson Daniel Wammanda5, Chika Ugochukwu6, Olubukula Adesina7, Eno Etim Nyong8, Frank Osungwu9, Shanti Pal10, Sylvester Chigozie Nwoasu11, Magnus Wallberg12, David Coulter13. 1. Department of Clinical Pharmacology and Therapeutics, College of Medical Sciences, PMB1069, University of Maiduguri, Maiduguri, Borno State, Nigeria. pubassi@gmail.com 2. National Pharmacovigilance Centre NAFDAC Abuja, FCT, Abuja, Nigeria. 3. Clinical Pharmacology Unit, University of Benin Teaching Hospital, Benin, Edo State, Nigeria. 4. Department of Paediatrics, Federal Medical Centre, Gombe, Gombe State, Nigeria. 5. Department of Paediatrics, Ahmadu Bello University Teaching Hospital, Zaria, Kaduna State, Nigeria. 6. Department of Paediatrics, Nnamdi Azikwe University Teaching Hospital, Enugu, Enugu State, Nigeria. 7. Department of Obstetrics and Gynaecology, University College Hospital, Ibadan, Oyo State, Nigeria. 8. Department of Paediatrics, University of Uyo Teaching Hospital, Uyo, Akwa-Ibom State, Nigeria. 9. MOPD Clinic, Nigerian Institutes for Pharmaceutical Research and Development, Idishin Abuja-FCT, Abuja, Nigeria. 10. WHO Department of Essential Medicine and Health Products, WHO, Geneva, Switzerland. 11. Department of Mathematics and Statistics, University of Maiduguri, Maiduguri, Borno State, Nigeria. 12. Uppsala Monitoring Centre, WHO Collaborating Centre for International Drug Monitoring, Uppsala, Sweden. 13. Private Consultant in Pharmacovigilance and Pharmacoepidemiology, Dunedin, New Zealand.
Abstract
BACKGROUND: A pilot programme of Cohort Event Monitoring (CEM) was conducted across the six geopolitical zones of Nigeria on patients treated for uncomplicated malaria with artemisinin-based combination therapy (ACT). The emergence and spread of malaria parasites resistant to commonly available antimalarial drugs necessitated a shift in policy for malaria treatment by the Federal Government from the use of chloroquine and sulphadoxine-pyrimethamine (SP) as first-line treatments to ACTs. Initial reports following deployment of ACTs in clinical settings raised safety concerns regarding their use. Although artemisinin and its derivatives are generally thought to be safe, there are currently few or no data on their safety among populations in Nigeria. OBJECTIVES: The main objectives of the CEM programme were to proactively determine the adverse event (AE) profile of artesunate/amodiaquine (AA) and artemether/lumefantrine (AL) in real-life settings and to find out the factors predisposing to AEs. METHODS: The CEM study was observational, longitudinal, prospective, and inceptional. Patients were observed in real-life situations. It was conducted in six public health facilities in Nigeria on patients with a clinical diagnosis of uncomplicated malaria treated with ACTs. Patients were prescribed one of the ACTs on an alternate basis as they enrolled into the programme. Follow-up reviews were undertaken on days 3 and 7 following commencement of ACT treatment. At follow-up, patients were evaluated for any clinical event that they might have experienced following the use of the ACTs. We report the result of this initial pilot in which 3,010 patients treated for uncomplicated malaria with AA or AL were enrolled. RESULTS: The seven most common AEs seen were general body weakness 25.0/36.6% (AL/AA); dizziness 11.9/17.2% (AL/AA); vomiting 8.0/10.2% (AL/AA); abdominal pain 8.5/7.2% (AL/AA); insomnia 6.3/5.9% (AL/AA); body pains 3.4/5.2 (AL/AA) %; anorexia 8.5/4.6% (AL/AA). Most adverse events occurred from day 1 and peaked by day 2 and 3 of medication with the mean duration of events being 3 days. By the end of the follow-up visit on day 7, the AEs had resolved in the majority of patients. Adverse events were more common in the AA group than AL revealing a better safety profile for AL (p < 0.001). Both ACTs demonstrated good ability to resolve the clinical symptoms of uncomplicated malaria. CONCLUSION: In conclusion, this pilot CEM programme suggests that adverse events with ACTs were common. However, serious life-threatening events were not common. It appears that ACTs have a tolerable safety profile among Nigerians.
BACKGROUND: A pilot programme of Cohort Event Monitoring (CEM) was conducted across the six geopolitical zones of Nigeria on <span class="Species">patients treated for uncomplicated malaria with artemisinin-based combination therapy (ACT). The emergence and spread of malaria parasites resistant to commonly available antimalarial drugs necessitated a shift in policy for malaria treatment by the Federal Government from the use of chloroquine and sulphadoxine-pyrimethamine (SP) as first-line treatments to ACTs. Initial reports following deployment of ACTs in clinical settings raised safety concerns regarding their use. Although artemisinin and its derivatives are generally thought to be safe, there are currently few or no data on their safety among populations in Nigeria. OBJECTIVES: The main objectives of the CEM programme were to proactively determine the adverse event (AE) profile of artesunate/amodiaquine (AA) and artemether/lumefantrine (AL) in real-life settings and to find out the factors predisposing to AEs. METHODS: The CEM study was observational, longitudinal, prospective, and inceptional. Patients were observed in real-life situations. It was conducted in six public health facilities in Nigeria on patients with a clinical diagnosis of uncomplicated malaria treated with ACTs. Patients were prescribed one of the ACTs on an alternate basis as they enrolled into the programme. Follow-up reviews were undertaken on days 3 and 7 following commencement of ACT treatment. At follow-up, patients were evaluated for any clinical event that they might have experienced following the use of the ACTs. We report the result of this initial pilot in which 3,010 patients treated for uncomplicated malaria with AA or AL were enrolled. RESULTS: The seven most common AEs seen were general body weakness 25.0/36.6% (AL/AA); dizziness 11.9/17.2% (AL/AA); vomiting 8.0/10.2% (AL/AA); abdominal pain 8.5/7.2% (AL/AA); insomnia 6.3/5.9% (AL/AA); body pains 3.4/5.2 (AL/AA) %; anorexia 8.5/4.6% (AL/AA). Most adverse events occurred from day 1 and peaked by day 2 and 3 of medication with the mean duration of events being 3 days. By the end of the follow-up visit on day 7, the AEs had resolved in the majority of patients. Adverse events were more common in the AA group than AL revealing a better safety profile for AL (p < 0.001). Both ACTs demonstrated good ability to resolve the clinical symptoms of uncomplicated malaria. CONCLUSION: In conclusion, this pilot CEM programme suggests that adverse events with ACTs were common. However, serious life-threatening events were not common. It appears that ACTs have a tolerable safety profile among Nigerians.
Authors: L von Seidlein; P Milligan; M Pinder; K Bojang; C Anyalebechi; R Gosling; R Coleman; J I Ude; A Sadiq; M Duraisingh; D Warhurst; A Alloueche; G Targett; K McAdam; B Greenwood; G Walraven; P Olliaro; T Doherty Journal: Lancet Date: 2000-01-29 Impact factor: 79.321
Authors: R Price; M van Vugt; L Phaipun; C Luxemburger; J Simpson; R McGready; F ter Kuile; A Kham; T Chongsuphajaisiddhi; N J White; F Nosten Journal: Am J Trop Med Hyg Date: 1999-04 Impact factor: 2.345
Authors: C I Fanello; C Karema; W van Doren; Chantal Van Overmeir; D Ngamije; U D'Alessandro Journal: Trans R Soc Trop Med Hyg Date: 2006-09-26 Impact factor: 2.184
Authors: T H Tran; N P Day; V C Ly; T H Nguyen; P L Pham; H P Nguyen; D B Bethell; X S Dihn; T H Tran; N J White Journal: Clin Infect Dis Date: 1996-12 Impact factor: 9.079
Authors: T H Tran; N P Day; H P Nguyen; T H Nguyen; T H Tran; P L Pham; X S Dinh; V C Ly; V Ha; D Waller; T E Peto; N J White Journal: N Engl J Med Date: 1996-07-11 Impact factor: 91.245
Authors: Alexander N O Dodoo; Carole Fogg; Edmund T Nartey; Germano L C Ferreira; George Obeng Adjei; William Kudzi; Abdul Malik Sulley; Augustina Kodua; David Ofori-Adjei Journal: Drug Saf Date: 2014-06 Impact factor: 5.606
Authors: Rita Baiden; Abraham Oduro; Tinto Halidou; Margaret Gyapong; Ali Sie; Eusebio Macete; Salim Abdulla; Seth Owusu-Agyei; Abdunoor Mulokozi; Alex Adjei; Esperanca Sevene; Guillaume Compaoré; Innocent Valea; Isaac Osei; Abena Yawson; Martin Adjuik; Raymond Akparibo; Bernhards Ogutu; Gabriel Leonard Upunda; Peter Smith; Fred Binka Journal: Malar J Date: 2015-04-15 Impact factor: 2.979
Authors: Serge-Brice Assi; Yapo Thomas Aba; Jean Claude Yavo; Abouo Franklin Nguessan; N'cho Bertin Tchiekoi; Koffi Moïse San; Emmanuel Bissagnéné; Stephan Duparc; Valérie Lameyre; Mea Antoine Tanoh Journal: Malar J Date: 2017-01-03 Impact factor: 2.979
Authors: Peter U Bassi; Adeline I Osakwe; Comfort K Ogar; Cassandra Elagbaje; Biyaya B Nwankwo; Sulayman T Balogun; Godwin N Ntadom; Ambrose O Isah Journal: Pharmacol Res Perspect Date: 2017-03-24
Authors: Alambo K Mssusa; Adam M Fimbo; Alex F Nkayamba; Henry F Irunde; Hiiti B Sillo; Danstan H Shewiyo; Geraldine Hill; Omary M Minzi Journal: Clin Drug Investig Date: 2016-05 Impact factor: 3.580
Authors: Comfort Kunak Suku; Geraldine Hill; George Sabblah; Mimi Darko; George Muthuri; Edward Abwao; Jayesh Pandit; Adeline Ijeoma Osakwe; Cassandra Elagbaje; Priscilla Nyambayo; Star Khoza; Alexander N Dodoo; Shanthi Narayan Pal Journal: Drug Saf Date: 2015-11 Impact factor: 5.606